from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A monoclonal antibody being investigated as a neuroprotector for patients with Alzheimer's disease.


-ne- +‎ -zu- +‎ -mab (Wiktionary)


  • Lilly said that it will continue development of another Alzheimer's drug called solanezumab, which is also in Phase 3 testing, the last phase of clinical trials. :

  • Eli Lilly is developing a high-profile treatment called solanezumab, after having scrapped another drug last year that worsened the ability of patients to perform daily activities.

    Reuters: Press Release

  • Lilly said it would continue two studies of solanezumab after the studies clear interim safety and futility analyses conducted by an independent committee overseeing the trials.

    Pfizer, Lilly Profits Fall as Drugs Lose Patents

  • Bernstein Research late last year estimated Lilly's Alzheimer's antibody, solanezumab, could generate $23 billion in sales by 2020 if it is shown to be safe and effective.

    Pfizer, Lilly Profits Fall as Drugs Lose Patents

  • Lilly Chief Executive John Lechleiter cautioned in an interview that observers shouldn't "over-interpret" the decision to complete the trials, and that it remains to be seen whether solanezumab is safe and effective.

    Pfizer, Lilly Profits Fall as Drugs Lose Patents

  • Pfizer's president of world-wide R&D, Mikael Dolsten , told analysts that there are some differences between bapineuzumab and solanezumab, and so the clinical results for one drug "may not be transferable" to the other drug.

    Pfizer, Lilly Profits Fall as Drugs Lose Patents

  • Also, it expects to report later this year results of late-stage testing of an experimental Alzheimer's disease drug, solanezumab.

    For Lilly, Rocky Year Ahead

  • The company noted that its decision to halt development of semagacestat doesn't affect ongoing clinical trials of its other late-stage Alzheimer's treatment, solanezumab.

    Lilly Halts Development

  • In 2008, Lilly struck a deal with outside investors TPG-Axon and Quintiles Transnational Corp. to receive funding of up to $325 million to help pay for the clinical trials of semagacestat and solanezumab.

    Lilly Halts Development

  • Other amyloid-clearing agents were already being looked at, he noted, including gantenerumab, solanezumab and bapineuzumab. - Telegraph online, Daily Telegraph, Sunday Telegraph


Log in or sign up to get involved in the conversation. It's quick and easy.